TY - JOUR
T1 - Children's Oncology Group's 2023 blueprint for research
T2 - Non-Hodgkin lymphoma
AU - the COG NHL Committee
AU - El-Mallawany, Nader Kim
AU - Alexander, Sarah
AU - Fluchel, Mark
AU - Hayashi, Robert J.
AU - Lowe, Eric J.
AU - Giulino-Roth, Lisa
AU - Wistinghausen, Birte
AU - Hermiston, Michelle
AU - Allen, Carl E.
N1 - Publisher Copyright:
© 2023 Wiley Periodicals LLC.
PY - 2023/9
Y1 - 2023/9
N2 - Pediatric non-Hodgkin lymphoma (NHL) includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the United States. Improvements in survival in NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes. As an example, survival for advanced Burkitt lymphoma is now >95%. Major remaining challenges include survival for relapsed and refractory disease and long-term morbidity in NHL survivors. Langerhans cell histiocytosis (LCH) was added to the NHL Committee portfolio in recognition of LCH as a neoplastic disorder and the tremendous unmet need for improved outcomes. The goal of the Children’ Oncology Group NHL Committee is to identify optimal cures for every child and young adult with NHL (and LCH). Further advances will require creative solutions, including engineering study groups to combine rare populations, biology-based eligibility, alternative endpoints, facilitating international collaborations, and coordinated correlative biology.
AB - Pediatric non-Hodgkin lymphoma (NHL) includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the United States. Improvements in survival in NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes. As an example, survival for advanced Burkitt lymphoma is now >95%. Major remaining challenges include survival for relapsed and refractory disease and long-term morbidity in NHL survivors. Langerhans cell histiocytosis (LCH) was added to the NHL Committee portfolio in recognition of LCH as a neoplastic disorder and the tremendous unmet need for improved outcomes. The goal of the Children’ Oncology Group NHL Committee is to identify optimal cures for every child and young adult with NHL (and LCH). Further advances will require creative solutions, including engineering study groups to combine rare populations, biology-based eligibility, alternative endpoints, facilitating international collaborations, and coordinated correlative biology.
KW - Langerhans cell histiocytosis
KW - clinical trial
KW - non-Hodgkin lymphoma
KW - pediatric oncology
UR - http://www.scopus.com/inward/record.url?scp=85165239028&partnerID=8YFLogxK
U2 - 10.1002/pbc.30565
DO - 10.1002/pbc.30565
M3 - Article
C2 - 37449925
AN - SCOPUS:85165239028
SN - 1545-5009
VL - 70
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - S6
M1 - e30565
ER -